Ocrelizumab, a new B-cell–targeted therapy for multiple sclerosis (MS), demonstrated efficacy in the treatment of relapsing and primary progressive MS (PPMS), according to a recent literature review, and is the first therapy approved for patients with PPMS. A comprehensive literature search was conducted using search terms “ocrelizumab” and “multiple sclerosis” using the date range of 1946 through October 2017. Investigators found:
- A phase II trial established 600 mg intravenously every 6 months as the preferred dosing schedule.
- 2 phase III trials evaluated the efficacy of ocrelizumab in patients with relapsing remitting MS, and individual and pooled analysis demonstrated a significant reduction in annualized relapse rate, disability progression at 12 weeks, and gadolinium-enhancing lesions on magnetic resonance imaging (MRI).
- Patients with PPMS were evaluated in a third phase III trial, which showed a significant decrease in disease progression at 12 weeks and volume of T2-weighted lesions on MRI.
Stahnke AM, Holt KM. Ocrelizumab: A new B-cell therapy for relapsing remitting and primary progressive multiple sclerosis. [Published online ahead of print December 12, 2017]. Ann Pharmacother. doi:10.1177/1060028017747635.
This Week's Must Reads
Midlife Risk Factors Linked to Late-Onset Epilepsy, JAMA Neurology; ePub 2018 Jul 23; Johnson, et al
Nearly 1 Million Adults ≥55 Years Have Epilepsy, Epilepsy Behav; ePub 2018 Aug 2; Sapkota, et al
Incidental Findings Common in Stroke Patients, J Stroke Cerebrovasc Dis; ePub 2018 Aug 2; Doyle, et al
Spatial Heterogeneity of White Matter Lesions , Neurology; ePub 2018 Aug 3; Habes, et al
Poor Sleep Linked to Slow Recovery from TBI, Sleep; ePub 2018 Jul 24; Kalmbach, Conroy, et al
Must Reads in Multiple Sclerosis
Perceived Stress and Sleep Quality in Those with MS, Mult Scler Relat Disord; ePub 2018 Jul 26; Lamis, et al
Perceived Need for Mental Health Care in MS, Mult Scler Relat Disord; ePub 2018 Jul 29; Orr, et al
Cerebellum and Cognition Assessed in Progressive MS, J Neurology; ePub 2018 Jul 28; Cocozza, et al
Major Neck Vessels Compromised in Patients with MS, Am J Neuroradiol; ePub 2018 Jul 26; Pelizzari, et al
Cognitive Impairment, Dysarthria in Multiple Sclerosis, Am J Speech Lang Pathol; ePub 2018 Jul 26; Feenaughty, et al